Valneva to Present on its Chikungunya Vaccine IXCHIQ, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. - Seite 3

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M [phone] [e-mail]

Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 [e-mail]

---

1 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ - Valneva
2 ACIP Vaccine Recommendations and Schedules | CDC
3 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 - Valneva

 

Attachment

• 2024_03_21_VLA_WVC_PR_EN_Final